111Boehringer_Ingelheim_Logo_RGB_Dark_Green (002).png
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
June 07, 2024 04:30 ET | Boehringer Ingelheim
News builds on previously announced primary endpoint, which showed up to 83.0% of adults achieved statistically significant improvement in metabolic dysfunction-associated steatohepatitis (MASH)...
111Boehringer_Ingelheim_Logo_RGB_Dark_Green (002).png
Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
May 28, 2024 07:00 ET | Boehringer Ingelheim
  International analysis of mental health provision in eight G20 countries reveals stigma, a shortage of mental health professionals and inconsistent availability and quality of care are creating...
111Boehringer_Ingelheim_Logo_RGB_Dark_Green (002).png
Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia
May 06, 2024 05:00 ET | Boehringer Ingelheim
Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic...
Poultry image
Less than half of veterinary professionals feel their profession is appreciated
April 25, 2024 03:00 ET | Boehringer Ingelheim
World Veterinary Day 2024 celebrates the essential work of veterinarians, yet new data show only 49% of veterinary professionals believe their profession is appreciated. Veterinary associations and...
boehringer_biopharmaceutical production_Biberach resized
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
April 16, 2024 04:35 ET | Boehringer Ingelheim
Human Pharma sales up 10.3%* to EUR 20.8 bn, driven by JARDIANCE® and OFEV®Animal Health sales up 6.9 %* to EUR 4.7 bn, fueled by new product launchesR&D expenditures increase by 14.2% to EUR 5.8...
111Boehringer_Ingelheim_Logo_RGB_Dark_Green (002).png
SPEVIGO® approved for expanded indications in China and the US
March 19, 2024 07:00 ET | Boehringer Ingelheim
Generalized pustular psoriasis (GPP) is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin and systemic symptoms, such as fever, pain, and fatigue1,2,3,4In China,...
111Boehringer_Ingelheim_Logo_RGB_Dark_Green (002).png
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
February 26, 2024 02:05 ET | Boehringer Ingelheim
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH)*, after meeting its primary and key secondary endpoint following 48 weeks of...
111Boehringer_Ingelheim_Logo_RGB_Dark_Green (002).png
New collaboration between Boehringer Ingelheim and Sleip leverages AI-technology to help detect lameness in horses
February 19, 2024 04:00 ET | Boehringer Ingelheim
The Sleip app uses artificial intelligence (AI) to provide objective analysis of a horse’s movement with just a smartphone. A new global commercial partnership between Boehringer Ingelheim...
111Boehringer_Ingelheim_Logo_RGB_Dark_Green (002).png
Boehringer expands production site in Greece for new medicine
January 11, 2024 10:15 ET | Boehringer Ingelheim
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, today announced a further expansion and upgrade of its plant in Koropi, Greece. With an investment of EUR 120 million, the...